Recital 54, Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 Decembe…

In forcesince 18 Dec 2006cited 1×

In order to avoid duplication of work, and in particular to avoid duplication of testing,

registrants of phase-in substances should pre-register as early as possible with a database managed by the Agency. A system should be established in order to provide for the establishment of Substance Information Exchange Fora (SIEF) to help exchange of information on the substances that have been registered. SIEF participants should include all relevant actors submitting information to the Agency on the same phase-in substance.

They should include both potential registrants, who must provide and be supplied with any information relevant to the registration of their substances, and other participants, who may receive financial compensation for studies they hold but are not entitled to request information. In order to ensure the smooth functioning of that system they should fulfil certain obligations. If a member of a SIEF does not fulfil his obligations, he should be penalised accordingly but other members should be enabled to continue preparing their own registration. In cases where a substance has not been pre-registered, measures should be taken to help downstream users find alternative sources of supply.

  • Judgment of the General Court (Fourth Chamber) of 29 March 2023 (Extracts). Nouryon Industrial Chemicals BV and Others v European CommissionDecision

    29 Mar 2023 · 62019TJ0868